Humanin

Unmodified 24-residue Humanin reference peptide for mitochondrial-stress research

Per batch COACAS 330936-69-1RUO

Research statusExtensively Studied

Supplied form24-residue linear peptide containing one methionine and one cysteine

Lead timeConfirmed with quote

Humanin — Lyophilized material; confirm released-lot appearance on the COA

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value: Humanin supports controlled studies of Bax/Bid-associated apoptosis, cytokine-receptor signaling, mitochondrial stress responses, endogenous biomarker measurement and structure-activity comparisons with distinct analogues
Neurodegeneration, metabolism, cardiovascular injury and aging findings are predominantly preclinical or observational and do not establish therapeutic or longevity benefits for this RUO material.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 330936-69-1
Formula: Confirm supplied form on batch COA
Molecular weight: 2687.28 Da
Appearance: Lyophilized material; confirm released-lot appearance on the COA
Purity: Per batch COA
Storage: Use the released-lot COA and stability statement. Define temperature, moisture and light protection, container closure, freeze-thaw allowance, solvent, concentration and adsorption controls. Because the sequence contains methionine and cysteine, explicitly monitor oxidation and disulfide-linked species rather than applying HNG solution-expiry claims to unmodified Humanin.
MOQ: On request
Lead time: Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Humanin

Humanin is a 24-residue peptide, MAPRGFSCLLLLTSEIDLPVKRRA, originally identified in a 2001 cell-expression screen for factors that opposed familial-Alzheimer's-disease-related neuronal death. It is widely studied as a mitochondrial-derived peptide and stress-signaling molecule. Endogenous Humanin measurements, cell studies and animal models support biomarker and mechanism research, but do not establish the safety or efficacy of administering synthetic Humanin. FDA GSRS contains a validated substance identity, but FDA states that UNII availability does not imply regulatory review or approval. This product is an RUO analytical/research reagent, not a finished dosage form.

Evidence contexts include apoptosis and mitochondrial stress mechanisms, neurotoxicity models, endogenous biomarker studies, metabolic models, cardiovascular injury models and aging/lifespan observations
Evidence must be labelled by analyte and model: unmodified Humanin, HNG/HNGF6A and Colivelin are not interchangeable, and no published randomized interventional human trial establishes a therapeutic indication for this product.

Mechanism context

The question the literature is testing

Cell and biochemical studies report that Humanin can interact with pro-apoptotic BAX and BID-family signaling, reducing mitochondrial membrane permeabilization in the tested systems. Other work reports interaction with IGFBP-3 and signaling through a CNTFRα/WSX-1/gp130-associated receptor complex. N-formylated Humanin also activates formyl-peptide receptors, but N-formylated Humanin is a chemically distinct analyte and its potency must not be assigned to this unmodified product. These pathways are model dependent and do not independently establish an administered human benefit.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context

Research areaMitochondrial research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Systematic safety and toxicology data for administering synthetic Humanin to humans are not established
Anti-apoptotic signaling can have context-dependent implications, so mechanistic cytoprotection should not be assumed universally beneficial
Handle as an RUO research chemical under an institutionally approved risk assessment and monitor oxidation/aggregation as experimental quality attributes; this record provides no human-use guidance.

Interactions reported in the literature

No combination-use guidance is provided
HNG/dexrazoxane studies concern a different analogue in a specific animal model; discussions of Humanin with MOTS-c, NAD+ precursors or other peptides do not constitute evidence for stacking or co-administration.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Humanin factory batch COAs

Humanin 10 mg Factory batch COA protected preview

Humanin10 mg · WHJLP-HUM10-260706-A

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require the complete 24-residue sequence and terminal state, high-resolution intact mass, an orthogonal identity method, peptide-content assay, chromatographic purity with impurity assignment, water, residual solvents, counterions and aggregate assessment
Explicitly control methionine/cysteine oxidation and disulfide-linked species
Appearance, HPLC area purity or solution clarity alone cannot prove identity, content or monomeric state.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

HUMANIN-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Use the released-lot COA and stability statement. Define temperature, moisture and light protection, container closure, freeze-thaw allowance, solvent, concentration and adsorption controls. Because the sequence contains methionine and cysteine, explicitly monitor oxidation and disulfide-linked species rather than applying HNG solution-expiry claims to unmodified Humanin.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Key sources: PubChem CID 16131438; FDA GSRS UNII H975EUX36G; Hashimoto et al., PNAS 2001; Guo et al., Nature 2003 (PMID 12732850); Ikonen et al., PNAS 2003 (PMID 14561895); Hashimoto et al. 2009 (PMCID PMC2695794); the cited 2020 lifespan/healthspan paper; Coradduzza et al. 2023 (PMCID PMC10135985); and the listed cardiovascular, diabetes and neuroprotection reviews. HNG pharmacokinetic, combination and stability studies characterize a different analogue and are retained only as boundary-setting context.

01
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ
Proceedings of the National Academy of Sciences of the United States of America (PNAS) · 2001 · peer-reviewed original research (foundational/landmark discovery paper)
Open source
02
Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults
Neuroscience Letters · 2002 · peer-reviewed original research
Open source
03
Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130
Molecular Biology of the Cell · 2009 · peer-reviewed original research (mechanism/receptor biology)
Open source
04
Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo
The Journal of Neuroscience · 2005 · peer-reviewed original research (humanin analog development)
Open source
05
The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan
Aging (Albany NY) · 2020 · peer-reviewed original research (cross-species aging/longevity study)
Open source
06
Humanin and Its Pathophysiological Roles in Aging: A Systematic Review
Biology (Basel) · 2023 · systematic review
Open source
07
Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives
Biology (Basel) · 2023 · review
Open source
08
The emerging role of the mitochondrial-derived peptide humanin in stress resistance
Journal of Molecular Endocrinology · 2013 · review
Open source

Product FAQ

Questions buyers ask about Humanin

How is unmodified Humanin distinguished from Humanin analogues?+

This catalog identity is the 24-residue sequence MAPRGFSCLLLLTSEIDLPVKRRA. Humanin-G (HNG, S14G), HNGF6A, Colivelin and N-formylated Humanin are chemically distinct analytes and can differ substantially in receptor activity, stability and model potency. An order and COA should state the complete sequence, terminal state and any formylation or other modification rather than using “Humanin” as an umbrella name.

Does Humanin research establish a human treatment or longevity effect?+

No. Direct evidence for synthetic unmodified Humanin is dominated by biochemical, cell and animal work on apoptosis and stress signalling. Human studies largely measure endogenous Humanin as a biomarker or association. Results from HNG, HNGF6A or Colivelin must not be assigned to this analyte, and no qualifying randomized interventional human trial establishes safety, efficacy or a longevity benefit for administered Humanin.

Which quality risks should be controlled for a Humanin lot?+

Request high-resolution intact mass, an orthogonal sequence method, chromatographic purity with impurity assignment and a separate peptide-content result. Because the sequence contains methionine and one cysteine, monitor methionine oxidation, cysteine oxidation and intermolecular disulfide-linked dimers or higher aggregates. Also define water, counterions, residual solvents, adsorption controls, storage and retest conditions; area purity alone does not establish content or monomeric state.

Humanin

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Humanin

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Humanin factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ

Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults

Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130

Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo

The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan

Humanin and Its Pathophysiological Roles in Aging: A Systematic Review

Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives

The emerging role of the mitochondrial-derived peptide humanin in stress resistance

Questions buyers ask about Humanin

Compare adjacent molecules and documentation needs.

Amino-1MQ

SLU-PP-332

SS-31

L-Carnitine